Byung Soo Im

Dr. Byung Soo Im

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2022 in Korean Journal of Radiology
Verified
Journal Article
Open access
PDF file
BIByung Soo Im
Byung Soo Im
DGDONG IL GWON
DONG IL GWON
HCHee Ho Chu
Hee Ho Chu
Jin Hyoung KimJin Hyoung Kim
Jin Hyoung Kim
GKGi-Young Ko
Gi-Young Ko
HYHyun-Ki Yoon
Hyun-Ki Yoon
Im BS, et al. Korean J Radiol. 2022 Jul;23:e54. https://doi.org/10.3348/kjr.2022.0204

5 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JKJihoon Kim
Jihoon Kim
Jin Hyoung KimJin Hyoung Kim
Jin Hyoung Kim
EKEunbyul Ko
Eunbyul Ko
JKJeong-Yeon Kim
Jeong-Yeon Kim
BIByung Soo Im
Byung Soo Im
IAIbrahim Alrashidi
Ibrahim Alrashidi
Background/Objectives: The Barcelona Clinic Liver Cancer (BCLC) staging system for hepatocellular carcinoma (HCC) was updated in 2022 to refine patient stratification, particularly in patients with intermediate-stage (BCLC B) HCC. Although transarterial chemoembolization (TACE) remains a key treatment for these patients, there is no prognostic model for survival outcomes based on the pretreatment factors of patients who meet the updated 2022 BCLC indications for TACE. The aim of this study was to develop a pretreatment risk model predicting overall survival (OS) in patients with intermediate-stage HCC and reclassified as candidates for TACE according to the updated 2022 BCLC criteria. Methods: This retrospective study included 658 HCC patients treated with first-line TACE according to the updated BCLC 2022 guidelines. Pretreatment factors such as the Child–Pugh score, tumor burden (up-to-11 criteria), bilobar tumor involvement, and serum alpha-fetoprotein (AFP) levels were analyzed. Cox proportional hazards models were used to identify significant predictors of OS, with these factors subsequently incorporated into a risk prediction model. Results: Significant predictors of OS included Child–Pugh score ≥ 7, bilobar tumor involvement, beyond up-to-11 criteria, and AFP ≥ 400 ng/mL. A risk model was developed using these factors, stratifying patients into low-, intermediate-, and high-risk groups. The median OS in the low-, intermediate-, and high-risk groups was 53, 35, and 21 months, respectively. Conclusions: The proposed pretreatment risk prediction model may be useful for predicting OS and guiding TACE candidacy in intermediate-stage HCC patients based on the updated 2022 BCLC guidelines.

27 April 2026 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
DGDONG IL GWON
DONG IL GWON
Jin Hyoung KimJin Hyoung Kim
Jin Hyoung Kim
HCHee Ho Chu
Hee Ho Chu
GKGun Ha Kim
Gun Ha Kim
JKJihoon Kim
Jihoon Kim
HYHyun-Ki Yoon
Hyun-Ki Yoon

22 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JKJihoon Kim
Jihoon Kim
Jin Hyoung KimJin Hyoung Kim
Jin Hyoung Kim
BIByung Soo Im
Byung Soo Im
GKGun Ha Kim
Gun Ha Kim
HCHee Ho Chu
Hee Ho Chu
SKSehee Kim
Sehee Kim
Background/Objectives: Management of hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) varies between systemic immunotherapy and locoregional approaches. We compared atezolizumab plus bevacizumab (Atezo–Bev) with locoregional therapy in treatment-naïve patients. Methods: We conducted a retrospective cohort study of patients with image- or biopsy-proven HCC and MVI, Child–Pugh A/B, and ECOG 0–1 who received first-line Atezo–Bev or locoregional therapy (transarterial chemoembolization [TACE] with or without external-beam radiotherapy [RT]). Inverse probability of treatment weighting (IPTW) minimized baseline imbalances. Primary outcomes were overall survival (OS) and progression-free survival (PFS). Modified RECIST assessed radiologic response, and major adverse events were classified using Society of Interventional Radiology criteria. Results: We analyzed 475 patients (Atezo–Bev, n = 191; locoregional therapy, n = 284). Baseline characteristics were similar, and IPTW achieved covariate balance. Median OS was 9.3 months with Atezo–Bev and 10.8 months with locoregional therapy; after IPTW, OS remained comparable (hazard ratio [HR] 0.95; 95% CI 0.76–1.19; p = 0.635). Median PFS was 6.0 versus 4.1 months, favoring Atezo–Bev; this persisted after IPTW (HR 0.64; 95% CI 0.52–0.79; p < 0.001). Objective response rates were similar (45% vs. 48%; p = 0.49). Major adverse events occurred in 11% of patients in both groups. Subgroup analyses showed no OS differences and a consistent PFS advantage with Atezo–Bev. Conclusions: In HCC with MVI, first-line Atezo–Bev achieved longer PFS than locoregional therapy, with comparable OS and safety, supporting Atezo–Bev as a valid and effective first-line option for disease control while locoregional modalities remain relevant within multidisciplinary care.

10 October 2025 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
EKEunbyeol Ko
Eunbyeol Ko
Jin Hyoung KimJin Hyoung Kim
Jin Hyoung Kim
JKJihoon Kim
Jihoon Kim
GKGun Ha Kim
Gun Ha Kim
HKHeung-Kyu Ko
Heung-Kyu Ko
GKGi-Young Ko
Gi-Young Ko

30 March 2026 in Korean Journal of Interventional Radiology
Verified
Journal Article
Open access
BIByung Soo Im
Byung Soo Im
JSJi Hoon Shin
Ji Hoon Shin
Korean Journal of Interventional Radiology